Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials
Wei J, Li B, Wang X, Li X, Hu Y, Qiao L, Zhou C, Yu P, Sang T, Zhu M, Wang Y · Frontiers in Pharmacology · 2022 April 28
DOI 10.3389/fphar.2022.893602
Objective
To systematically evaluate the efficacy and safety of Qili Qiangxin Capsule (QQC) in the treatment of dilated cardiomyopathy (DCM).
Conclusions
Compared with the control group, Qili Qiangxin Capsule (QQC) combined with CWM may be effective in treating dilated cardiomyopathy (DCM).
Critical Appraisal
Published research can offer valuable insights, but a paper’s conclusions may go beyond what its results support. Critical appraisal examines the methods, findings and limitations to clarify what can reasonably be concluded—and what remains uncertain.
This article has not yet been critically appraised by the Research Hub.
Learn more about Critical Appraisal
